4.1.1.28: aromatic-L-amino-acid decarboxylase
This is an abbreviated version!
For detailed information about aromatic-L-amino-acid decarboxylase, go to the full flat file.
Word Map on EC 4.1.1.28
-
4.1.1.28
-
dopaminergic
-
serotonin
-
parkinsonism
-
monoamine
-
striatum
-
catecholamine
-
neurotransmitter
-
carbidopa
-
noradrenaline
-
levodopa
-
norepinephrine
-
benserazide
-
5-hydroxytryptamine
-
substantia
-
dopac
-
serotonergic
-
tryptamine
-
nigrostriatal
-
catharanthus
-
catechol-o-methyltransferase
-
roseus
-
beta-hydroxylase
-
5-hydroxyindoleacetic
-
homovanillic
-
3,4-dihydroxyphenylacetic
-
catecholaminergic
-
dyskinesia
-
dopamine-beta-hydroxylase
-
alpha-methyl-p-tyrosine
-
5-hiaa
-
pargyline
-
strictosidine
-
monoaminergic
-
raphe
-
l-dopa-induced
-
l-dihydroxyphenylalanine
-
apomorphine
-
antiparkinsonian
-
gamma-butyrolactone
-
tuberoinfundibular
-
autoreceptors
-
3-methoxytyramine
-
quinpirole
-
entacapone
-
catecholamine-synthesizing
-
dihydroxyphenylacetic
-
non-dopaminergic
-
phenylethanolamine
-
pharmacology
-
analysis
-
6-hydroxydopamine-lesioned
-
medicine
-
drug development
-
synthesis
-
tolcapone
- 4.1.1.28
-
dopaminergic
- serotonin
- parkinsonism
-
monoamine
- striatum
- catecholamine
-
neurotransmitter
- carbidopa
- noradrenaline
- levodopa
- norepinephrine
- benserazide
- 5-hydroxytryptamine
-
substantia
-
dopac
-
serotonergic
- tryptamine
-
nigrostriatal
- catharanthus
- catechol-o-methyltransferase
- roseus
- beta-hydroxylase
-
5-hydroxyindoleacetic
-
homovanillic
-
3,4-dihydroxyphenylacetic
-
catecholaminergic
- dyskinesia
- dopamine-beta-hydroxylase
- alpha-methyl-p-tyrosine
-
5-hiaa
- pargyline
- strictosidine
-
monoaminergic
-
raphe
-
l-dopa-induced
- l-dihydroxyphenylalanine
- apomorphine
-
antiparkinsonian
- gamma-butyrolactone
-
tuberoinfundibular
-
autoreceptors
- 3-methoxytyramine
- quinpirole
- entacapone
-
catecholamine-synthesizing
-
dihydroxyphenylacetic
-
non-dopaminergic
- phenylethanolamine
- pharmacology
- analysis
-
6-hydroxydopamine-lesioned
- medicine
- drug development
- synthesis
- tolcapone
Reaction
Synonyms
3,4-dihydroxyphenylalanine carboxylase, 3,4-Dihydroxyphenylalanine decarboxylase, 5-Hydroxy-L-tryptophan decarboxylase, 5-Hydroxytryptophan decarboxylase, 5-hydroxytryptophan hydroxylase, 5HTP decarboxylase, AAAC, AAAD, AACD, AADC, AADC1A, AADC1B, AADC393, AADC438, AADC486, Alt-DDC, aromatic acid acid decarboxylase, Aromatic amino acid decarboxylase, aromatic amino acid decarboxylase 1A, aromatic amino acid decarboxylase 1B, Aromatic L-amino acid decarboxylase, aromatic L-aminoacid decarboxylase, aromatic-L-amino-acid decarboxylase, CrTDC, DDC, Decarboxylase, aromatic amino acid, Di-ADC, Dihydroxyphenylalanine-5-hydroxytryptophan decarboxylase, DOPA DC, dopa decarboxilase, DOPA decarboxylase, DOPA-5-hydroxytryptophan decarboxylase, DOPA/5HTP decarboxylase, dopamine decarboxylase, EC 4.1.1.26, EC 4.1.1.27, HsDDC, Hydroxytryptophan decarboxylase, L-3,4-Dihydroxyphenylalanine decarboxylase, L-5-Hydroxytryptophan decarboxylase, L-amino acid decarboxylase, L-amino-acid decarboxylase, L-Aromatic amino acid decarboxylase, L-aromatic aminoacid decarboxylase, L-DOPA decarboxylase, L-Tryptophan decarboxylase, neural-type DDC, non-neural DDC, PP_2552, TDC, TDC2, Tenebrio Dopa decarboxylase, Trp decarboxylase, Tryptophan decarboxylase, tryptophan decarboxylase-1, tryptophan decarboxylase-2, TYDC, Tydc9, Tyrosine/Dopa decarboxylase
ECTree
4.1.1.28 aromatic-L-amino-acid decarboxylaseAdvanced search results
results (
results (Activating Compound
Activating Compound on EC 4.1.1.28 - aromatic-L-amino-acid decarboxylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
ACTIVATING COMPOUND 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
amantadine
-
drug acting on glutamatergic receptor type enhances AAAD activity
budipine
-
drug acting on glutamatergic receptor type enhances AAAD activity
cGMPdependent protein kinase Ialpha
phosphorylates and activates neuronal AAAD, maximal increase of activity is obtained at about 100-175 units during a 10 min incubation at 30°C
-
clonidine
-
drug acting on alpha adrenergic receptor type enhances AAAD activity
dextrometorphan
-
drug acting on glutamatergic receptor type enhances AAAD activity
forskolin
-
intracerebroventricularly injection enhances the enzyme activity, a response, that can be blocked by selective inhibitors of protein kinase A
L-745,870
-
enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist
L-Dopa
-
L-DOPA treatment (20-200 microM) increases the levels of dopamine by 226%-504% after 3-6 h of treatment and enhances the activities of tyrosine hydroxylase and aromatic L-amino acid decarboxylase
memantine
-
drug acting on glutamatergic receptor type enhances AAAD activity
phencyclidine
-
drug acting on glutamatergic receptor type enhances AAAD activity
phorbol-12,13-myristic acid
-
intracerebroventricularly injection enhances the enzyme activity, a response, that can be blocked by selective inhibitors of protein kinase A
pimozide
-
enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist
remoxipride
-
enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist
SCH 23390
-
enhanced AAAD activity in the striatum by acute and chronic treatment with the D1-like receptor antagonist
SKF 38393
-
enhanced AAAD activity in the striatum by chronic treatment with the D1-like receptor agonist
sulpiride
-
enhanced AAAD activity by in the striatum by acute and chronic treatment with the D2-like receptor antagonist
clozapine
-
enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist
flupenthixol
-
enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist
haloperidol
-
enhanced AAAD activity in the striatum by acute and chronic treatment with the D2-like receptor antagonist
haloperidol
-
enhanced AAAD activity in the striatum by acute and chronic treatment with the D2-like receptor antagonist
pyridoxal 5'-phosphate
-
stimulated by addition of excess pyridoxal phosphate
spiperone
-
enhanced AAAD activity in the striatum by acute and chronic treatment with the D2-like receptor antagonist
additional information
-
A conserved AP-1 (JNK activated transcription factor complex) binding upstream of the DDC transcription start site is necessary to induce DDC transcription
-
additional information
-
aseptic wounding of larvae or adults does not lead to DDC transcriptional induction, unlike in embryos where DDC activity at the edge of the wound contributes to the formation of a melanin clot
-
additional information
-
Transcription of the dopa decarboxylase gene is induced in response to gram-negative and gram-positive septic injury, but not aseptic wounding. Ddc transcripts are detectible within 2 h and remain high for several hours following infection with either gram-negative (Escherichia coli) or gram-positive (Staphylococcus aureus) bacteria. Ddc transcription depends on a previously uncharacterized member of the p38 mitogen-activated protein kinase family, p38c
-
additional information
-
activation in vivo occurs in response to the acute action of physiological stimuli, drugs that act at neurotransmitter receptors, or modulation of the activity of endogenous kinases and phospatases
-
additional information
-
DDC is overexpressed, at the mRNA level, in the specimens from prostate cancer patients, in comparison to those from benign prostate hyperplasia patients. High expression levels of DDC are found more frequently in high Gleason's score tumors as well as in advanced stage patients.
-
additional information
-
high expression of DDC in blood and bone marrow corresponds to metastatic neuroblastoma at diagnosis, residual disease, and poor outcome
-
additional information
-
relative to obtained dose of Adeno-associated virus type 2 including human AADC gene, high dose-dependent levels of cDNA are detected
-
additional information
-
the early activation of AAAD is followed by a late, longer lasting (hours) response, which is accompanied by an increase of mRNA and protein
-
additional information
-
pyridoxal 5'-phosphate deficiency reduces AADC activity
-
additional information
-
activation in vivo occurs in response to the acute action of physiological stimuli, drugs that act at neurotransmitter receptors, or modulation of the activity of endogenous kinases and phospatases
-
additional information
-
the early activation of AAAD is followed by a late, longer lasting (hours) response, which is accompanied by an increase of mRNA and protein
-
additional information
-
injection of Escherichia coli increases enzyme activity
-
